Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
29 Results for "
subcutaneous tumor model
" in MedChemExpress (MCE) Product Catalog:
Products (29)
29 Results for "subcutaneous tumor model" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
DOTA-NHS-ester is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
1
1 Cited Publications
Cat. No.: HY-163001
CAS No.: 2408008-21-7
1
1 Cited Publications
Cat. No.: HY-128890B
Purity: 95.00%
Target:
Research Areas:
DOTA-NHS-ester TFA is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester TFA can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester TFA can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
Synonyms: ABSK011
Irpagratinib (ABSK011) is an orally active FGFR4 inhibitor (IC50<10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model .
Cat. No.: HY-P9992
CAS No.: 2414550-93-7
Synonyms: BAY-2315497; PSMA-TTC
Cat. No.: HY-P99925
CAS No.: 1192578-27-0
Synonyms: REGN421
Target:
Research Areas:
Cat. No.: HY-175870
CAS No.: 3024878-19-8
Eras-4001 is a potent, orally active pan-KRAS inhibitor with Kd values of 110, 13 and 39 pM against wild-type, G12D and G12V mutant KRAS, respectively, and exhibits selectivity toward wild-type HRAS and NRAS. Eras-4001 inhibits ERK1/2 phosphorylation and cell viability in cancer cells. Eras-4001 induces tumor growth inhibition and regression in subcutaneous xenograft models. Eras-4001 can be used in research on non-small cell lung cancer, ovarian cancer, etc.
Target:
Research Areas:
DZD1516 is an orally active, reversible, blood-brain barrier (BBB)-penetrant selective HER2 tyrosine kinase inhibitor with an IC50 of 0.56 nM against HER2. DZD1516 is not a substrate of P-gp or BCRP, and exhibits high passive permeability. DZD1516 inhibits tumor growth in HER2-positive brain metastasis, leptomeningeal metastasis and subcutaneous xenograft models, and can be used for research related to HER2-positive breast cancer and central nervous system metastasis .
Cat. No.: HY-172351B
CAS No.: 24991-53-5
Cat. No.: HY-174984
CAS No.: 3098437-66-9
VCP/p97 IN-3 is a VCP/p97 allosteric inhibitor. VCP/p97 IN-3 shows the inhibitory activity against the VCP proteins with an IC50 of 9 nM and the mutant VCP proteins with IC50 of 12 nM (N660K) and 19 nM (V474A/D649A). VCP/p97 IN-3 increases K48-linked ubiquitination and the level of cleaved caspase-3. VCP/p97 IN-3 activates ER-stress and the UPR. VCP/p97 IN-3 inhibits tumor growth in RPMI-8226 cell subcutaneous xenograft mouse models. VCP/p97 IN-3 can be used for the study of multiple myeloma .
Cat. No.: HY-144720
CAS No.: 2616813-99-9
Target:
Research Areas:
YH-IV-173 is a BRG1 (SMARCA4) bromodomain binder with higher affinity for BRG1 than for BRM. YH-IV-173 acts as a sensitizing agent when combined with Temozolomide (HY-17364), modulating glioblastoma (GBM) cell proliferation and tumor growth. YH-IV-173 treatment alone shows weak effects on glioblastoma cell growth and tumor growth .
Cat. No.: HY-P5520
CAS No.: 2413262-74-3
Research Areas:
Cat. No.: HY-128890A
CAS No.: 1823122-52-6
Target:
Research Areas:
DOTA-NHS-ester hexafluorophosphate TFA is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester hexafluorophosphate TFA can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester hexafluorophosphate TFA can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
Cat. No.: HY-172364
Target:
Research Areas:
PLK1-IN-12 is a highly selective and orally active PLK1 inhibitor with an IC50 of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .
Cat. No.: HY-174330
Target:
Research Areas:
TRK-IN-31 is an orally active TRK inhibitor with an IC50 of 1.8 nM. TRK-IN-31 has superior antiproliferative activity in the Ba/F3-MPRIP-TRKA G667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 significantly inhibits tumor growth in Ba/F3-MPRIP-TRKA G667C subcutaneous tumor mice model .
Cat. No.: HY-174330A
Target:
Research Areas:
TRK-IN-31 hydrochloride is an orally active TRK inhibitor with an IC50 of 1.8 nM. TRK-IN-31 hydrochloride has superior antiproliferative activity in the Ba/F3-MPRIP-TRKA G667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 hydrochloride significantly inhibits tumor growth in Ba/F3-MPRIP-TRKA G667C subcutaneous tumor mice model .
Cat. No.: HY-146615
CAS No.: 2642224-22-2
Target:
Research Areas:
Axl-IN-6 (compound 14) is an orally active and potent AXL inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model .
Cat. No.: HY-175542
Research Areas:
KB-15 is a STAT3 inhibitor. KB-15 exhibits potent anti-proliferative activity against AGS gastric cancer cells (IC50 = 0.29 μM) and BGC-823 gastric cancer cells (IC50 = 0.65 μM). KB-15 exerts anti-tumor effects by inhibiting STAT3 phosphorylation, downregulating HO-1 expression, and promoting intracellular ROS accumulation. KB-15 induces G0/G1 phase cell cycle arrest and apoptosis, as well as suppresses colony formation and migration of gastric cancer cells. KB-15 demonstrates excellent anti-tumor efficacy in BGC-823 subcutaneous xenograft model. KB-15 can be used for the study of gastric cancer .
Cat. No.: HY-P11618
Target:
Research Areas:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
